MHRA Corrects Fosamax Advertising Complaint
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck Sharp & Dohme promotional materials do not directly refer to Teva UK Limited's generic alendronic acid, the U.K. agency now says.
You may also be interested in...
Merck Withdraws Fosamax UK Ad Claiming Superiority To Generic
UK Merck subsidiary issues corrective statement acknowledging no superiority over Teva’s generic alendronic acid, as required by the British Medicines & Healthcare products Regulatory Agency.
Tarceva Pancreatic Cancer Indication Turned Down In The EU
Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.
Teva To Investigate High-Dose Copaxone
A Phase III trial will compare 40 mg/day glatiramer to the 20 mg/day approved dose.